KM Biologics Co., Ltd.
↗Kumamoto, Japan
KM Biologics is a leading Japanese biopharmaceutical company specializing in the development, manufacture, and supply of human and veterinary vaccines, as well as blood plasma-derived products. Established in 2018, it took over the operations of the Chemo-Sero-Therapeutic Research Institute (Kaketsuken) and now operates as a core subsidiary of Meiji Holdings Co., Ltd. The company is a critical pillar of Japan's public health infrastructure, providing essential vaccines for the national immunization program.
KM Biologics is one of the few companies globally capable of producing smallpox and mpox vaccines (LC16m8 strain). It is currently at the forefront of next-generation vaccine technology in Japan, including the commercialization of the world's first self-amplifying mRNA (sa-RNA) COVID-19 vaccine in partnership with Arcturus Therapeutics and CSL Seqirus.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Vaccines & Plasma-derived Therapies
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$1B-$2B
Founded:2018
Ownership:subsidiary
Status:operating
FUNDING
Stage:Late Stage (Subsidiary)
Investors:Meiji Holdings Co., Ltd., Kumamoto Prefecture (Historical support), Japanese Government (AMED grants)
STOCK
Exchange:TYO (Parent: 2269)
Ticker:2269
Market Cap:$7.5B (Parent)
PIPELINE
Stage:Commercial
Lead Drug Stage:Approved (Kostaive, LC16m8)
Modalities:Inactivated vaccines, Live attenuated vaccines, sa-RNA, Plasma fractionation, Recombinant proteins
Active Trials:12
Trial Phases:Phase 1: 3 | Phase 2: 4 | Phase 3: 5
FDA Approvals:0
EMA Approvals:1
CORPORATE STRUCTURE
Parent Company:Meiji Holdings Co., Ltd.
Acquired By:Meiji Holdings Co., Ltd. (2018-07-01)
Subsidiaries:Meiji Animal Health Co., Ltd.
Key Partnerships:CSL Seqirus (sa-RNA distribution), Arcturus Therapeutics (sa-RNA development), Osivax (Universal Influenza vaccine), Meiji Seika Pharma (Global sales & marketing)
COMPETITION
Position:Leader
Competitors:Takeda Pharmaceutical, Daiichi Sankyo, Biken (The Research Foundation for Microbial Diseases of Osaka University), Sanofi, GSK
LEADERSHIP
Key Executives:
Hirotada Takahashi - President and Representative Director
Toshiaki Nagasato - Chairman and Representative Director
Board Members:Hirotada Takahashi, Toshiaki Nagasato, Jun Hishinuma, Hiromasa Takizawa
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with KM Biologics Co., Ltd.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.